- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hepatitis C Birth Cohort Screening is Cost-Effective
Birth cohort screening can be a cost-effective strategy to identify individuals infected with hepatitis C virus (HCV), according to a study published online Nov. 4 in the Annals of Internal Medicine.
Investigators from the National Opinion Research Center at the University of Chicago in Atlanta found that, compared to the current system, an additional 808,580 cases of chronic HCV were detected through birth cohort screening.
“Birth cohort screening for HCV in primary care settings was highly cost-effective,” the authors write.
Further details are available at: http://www.mdnews.com/news/hd/2011_45/hd_658577
Sources: HealthDay; MDNews.com
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen
